menu
    • menu

    Company profile for MBX Biosciences

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    MBX Biosciences is a preclinical-stage biotech company committed to creating therapies to treat rare endocrine diseases where there is inadequate treatment available. MBX’s leadership team has collaborated successfully over several decades to discover, develop and commercialize first-in-class endocrine therapeutics. A distinguishing strength of MBX is world-class proprietary peptide drug discovery.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MBX BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    11711 N. Meridian Street, Suite 310, Carmel, IN 46032
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://mbxbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mbx-biosciences-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MBX Biosciences To Join 37th Piper Sandler Healthcare Conference
    MBX Biosciences To Join 37th Piper Sandler Healthcare Conference

    18 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/18/3189927/0/en/MBX-Biosciences-to-Participate-in-the-37th-Annual-Piper-Sandler-Healthcare-Conference.html

    GLOBENEWSWIRE
    18 Nov 2025
    Share Share
    MBX Biosciences To Participate In November Investor Conferences
    MBX Biosciences To Participate In November Investor Conferences

    20 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/20/3169301/0/en/MBX-Biosciences-to-Participate-in-November-Investor-Conferences.html

    GLOBENEWSWIRE
    20 Oct 2025
    Share Share
    Mbx Biosciences Joins Stifel 2025 Virtual Cardiometabolic Forum
    Mbx Biosciences Joins Stifel 2025 Virtual Cardiometabolic Forum

    29 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/29/3157655/0/en/MBX-Biosciences-to-Participate-in-the-Stifel-2025-Virtual-Cardiometabolic-Forum.html

    GLOBENEWSWIRE
    29 Sep 2025
    Share Share
    Mbx Biosciences Reports Canvuparatide Success In Phase 2 Trial
    Mbx Biosciences Reports Canvuparatide Success In Phase 2 Trial

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153770/0/en/MBX-Biosciences-Announces-Once-Weekly-Canvuparatide-Achieved-Primary-Endpoint-in-Phase-2-Trial-with-63-Responder-Rate-at-12-Weeks-79-Responder-Rate-at-6-Months-in-Open-Label-Extens.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    MBX Biosciences Announces Proposed Public Offering
    MBX Biosciences Announces Proposed Public Offering

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3154306/0/en/MBX-Biosciences-Announces-Proposed-Public-Offering.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    MBX Biosciences to Share Ph 2 Topline Results of Canvuparatide
    MBX Biosciences to Share Ph 2 Topline Results of Canvuparatide

    19 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/19/3153399/0/en/MBX-Biosciences-to-Provide-Topline-Results-from-its-Phase-2-Trial-of-Potential-Once-Weekly-Canvuparatide-for-Hypoparathyroidism-HP-on-Monday-September-22.html

    GLOBENEWSWIRE
    19 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search